EA202190454A1 - Новый crispr-ассоциированный белок и его применение - Google Patents

Новый crispr-ассоциированный белок и его применение

Info

Publication number
EA202190454A1
EA202190454A1 EA202190454A EA202190454A EA202190454A1 EA 202190454 A1 EA202190454 A1 EA 202190454A1 EA 202190454 A EA202190454 A EA 202190454A EA 202190454 A EA202190454 A EA 202190454A EA 202190454 A1 EA202190454 A1 EA 202190454A1
Authority
EA
Eurasian Patent Office
Prior art keywords
associated protein
crispr
applications
present
protein
Prior art date
Application number
EA202190454A
Other languages
English (en)
Inventor
Сонхва Чое
Хан Сон Ким
Тон Ук Ким
Чончин Парк
Чиюн Юн
Original Assignee
Джи+ФЛАС ЛАЙФ САЙЕНСИЗ
СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи+ФЛАС ЛАЙФ САЙЕНСИЗ, СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН filed Critical Джи+ФЛАС ЛАЙФ САЙЕНСИЗ
Publication of EA202190454A1 publication Critical patent/EA202190454A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому CRISPR-ассоциированному белку и к его применению. Белок, имеющий аминокислотную последовательность SEQ ID NO: 1 или SEQ ID NO: 3, в соответствии с настоящим изобретением обладает эндонуклеазной активностью, способной распознавать и расщеплять внутриклеточную нуклеотидную последовательность, связанную с направляющей РНК. Следовательно, новый CRISPR-ассоциированный белок по настоящему изобретению можно использовать в качестве другой нуклеазы для редактирования генома в системе CRISPR-Cas.
EA202190454A 2018-08-09 2019-08-09 Новый crispr-ассоциированный белок и его применение EA202190454A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180093336 2018-08-09
PCT/KR2019/010110 WO2020032711A1 (ko) 2018-08-09 2019-08-09 신규한 crispr 연관 단백질 및 이의 용도

Publications (1)

Publication Number Publication Date
EA202190454A1 true EA202190454A1 (ru) 2021-04-22

Family

ID=69415629

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190454A EA202190454A1 (ru) 2018-08-09 2019-08-09 Новый crispr-ассоциированный белок и его применение

Country Status (15)

Country Link
US (1) US20210292722A1 (ru)
EP (1) EP3835418A4 (ru)
JP (2) JP2021532819A (ru)
KR (2) KR102096592B1 (ru)
CN (1) CN112567031B (ru)
AU (1) AU2019319377A1 (ru)
BR (1) BR112021002476A2 (ru)
CA (1) CA3109105A1 (ru)
EA (1) EA202190454A1 (ru)
IL (1) IL280631A (ru)
MX (1) MX2021001578A (ru)
PH (1) PH12021550256A1 (ru)
SG (1) SG11202101227TA (ru)
WO (1) WO2020032711A1 (ru)
ZA (1) ZA202101250B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
KR102497690B1 (ko) * 2020-09-22 2023-02-10 (주)지플러스생명과학 신규한 crispr 연관 단백질 및 이의 용도
US20230374478A1 (en) * 2020-09-22 2023-11-23 G Flas Life Sciences Modified cas12a protein and use thereof
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024167317A1 (ko) * 2023-02-10 2024-08-15 주식회사 엔세이지 신규 CRISPR/Cas12a 조성물 및 이의 표적 핵산 검출 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
AU2016299271B2 (en) * 2015-07-25 2022-09-22 Habib FROST A system, device and a method for providing a therapy or a cure for cancer and other pathological states
WO2017083722A1 (en) * 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
ES2735773T3 (es) * 2015-12-04 2019-12-20 Caribou Biosciences Inc Acidos nucleicos manipulados dirigidos a ácidos nucleicos
WO2017099494A1 (ko) * 2015-12-08 2017-06-15 기초과학연구원 Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도
US20190264186A1 (en) * 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
WO2017184786A1 (en) * 2016-04-19 2017-10-26 The Broad Institute Inc. Cpf1 complexes with reduced indel activity
WO2018013990A1 (en) 2016-07-15 2018-01-18 Zymergen Inc. Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
EP3526326A4 (en) * 2016-10-12 2020-07-29 The Regents of The University of Colorado, A Body Corporate NEW MODIFIED AND CHEMERICAL NUCLEASES
KR20180018466A (ko) * 2017-11-10 2018-02-21 주식회사 툴젠 면역세포의 면역조절 유전자의 활성 조절을 위한 조성물 및 그 용도

Also Published As

Publication number Publication date
CN112567031A (zh) 2021-03-26
KR102096592B1 (ko) 2020-04-02
IL280631A (en) 2021-03-25
WO2020032711A1 (ko) 2020-02-13
AU2019319377A1 (en) 2021-03-11
CA3109105A1 (en) 2020-02-13
ZA202101250B (en) 2022-09-28
MX2021001578A (es) 2021-06-15
BR112021002476A2 (pt) 2021-07-27
SG11202101227TA (en) 2021-03-30
EP3835418A1 (en) 2021-06-16
JP2024099604A (ja) 2024-07-25
CN112567031B (zh) 2024-08-06
KR102096604B1 (ko) 2020-04-02
PH12021550256A1 (en) 2021-11-03
KR20200018345A (ko) 2020-02-19
KR20200018364A (ko) 2020-02-19
EP3835418A4 (en) 2022-05-04
US20210292722A1 (en) 2021-09-23
JP2021532819A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
MX2020004578A (es) Composiciones de casz y metodos de uso.
EA201991440A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
GB2569734A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
PH12017502281A1 (en) Thermostable cas9 nucleases
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
WO2019006471A3 (en) NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
FI3604532T3 (fi) Uusia crispr-entsyymejä ja järjestelmiä
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX2018010288A (es) Sistema de transposon y metodos de uso.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA201590794A8 (ru) Рекомбинантные нейротоксины clostridium botulinum
MX2020011083A (es) Proteina.
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
PH12017502323A1 (en) Novel xylanase
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2016130628A8 (en) Griffithsin mutants
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
PE20170941A1 (es) Genes de tolerancia a herbicidas y metodos para usar los mismos
EP3950939A3 (en) Lipase variants and polynucleotides encoding same
EA202190758A1 (ru) Композиция для индукции гибели клеток, имеющих мутированный ген, и способ индукции гибели клеток, имеющих мутированный ген, с применением композиции